PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting held on April 8, 2026, with a large majority. The meeting took place at the Chollerhalle in Zug, with 26,780,855 shares represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting in 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee. The shareholders also approved the re-election of the Statutory Auditors and the Independent Proxy, as well as the maximum aggregate amount of compensation for the Board of Directors and Executive Committee.
Discharge was granted to all members of the Board of Directors and Executive Committee for their activities in the financial year 2025. The Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for 2025 were approved, along with the Remuneration Report 2025 in a separate consultative vote. The minutes of the AGM 2026 will be available within 15 days on the Company’s website.
The strong shareholder support underscores confidence in PolyPeptide's strategic direction and governance. As a specialized CDMO, PolyPeptide plays a critical role in the growing peptide therapeutics market, particularly in metabolic diseases including GLP-1. The company operates six GMP-certified facilities globally and continues to support pharmaceutical and biotech clients from pre-clinical to commercial stages.
The next annual General Meeting is scheduled for April 7, 2027. For more information, visit polypeptide.com or follow PolyPeptide on LinkedIn.
